Disruptionother · August 20, 2026

Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical on two insulin analogues

A new licensing deal adds supply access for two insulin analogues, shifting pharmaceutical input availability.

The trace

How it reaches your house.

Starting from Recombinant Insulin API (Bulk Drug Substance), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.

First impact
Recombinant Insulin API (Bulk Drug Substance) →supply up
Insulin
Recombinant insulin API is a critical, near-direct input to insulin, so added access should materially raise insulin supply.
93% confidence
Recombinant Insulin API (Bulk Drug Substance) →supply up
Novo NordiskNVO
With 45% exposure and a long 36-month replacement lead time, more API should ease Novo Nordisk's insulin production constraints.
80% confidence
Recombinant Insulin API (Bulk Drug Substance) →supply up
Eli Lilly and Company

Where it lands

What you buy, and what you own.

Goods you buy

Insulin

Companies you may own

NVOLLYSNYIntas Pharmaceuticals / Accord HealthcareBIOCON.NS

Tap a company to see what it told the SEC could break it.

In the MyPRIA app, this is checked against your own holdings.

← World Watch